President of the Congress Imre Földesi Scientific Organizing Committee János Kappelmayer Contents Abstracts Oral Communications Plenary Lectures Hematology diagnostics section SE1.1-6 Endocrinology and new biomarkers section SE2.1-5 AI and congenital disorders section SE3.1-6 Laboratory testing of drug effects section SE4.1-5 Varia section SE5.1-6 Autoimmunity and allergy tests section SE6.1-6 Symposium – Abbott CS1.1-2 Symposium – 77 Elektronika CS2.1-2 Symposium – Biomarker CS3.1-2 Symposium – Diagnosticum CS4.1 Symposium – Beckman Coulter CS5.1-3 Symposium – AstraZeneca CS6.1-2 Symposium CS7.1 Poster Presentations Poster section - I PS1.1-15 Poster section - II PS2.1-12 Poster section - III PS3.1-16 Poster section - IV PS4.1-13 Author index ORAL PRESENTATIONS Abstr. Nr. SE1.1 Applicability of laboratory algorithms at a university laboratory in anemia and body fluid analysis Hevessy Z., Kürti G.-Szabó E., Baráth S., Bartha-Tatár A., Tóth G., Kappelmayer J. Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary Background: We have developed previously a complete and efficient algorithm for laboratory medicine physicians for the differential diagnosis of anemia. We have also introduced an algorithm for cell counting in body fluids (BF) recently. We aimed to test the applicability of these algorithms in the routine workflow. Methods: We collected the HGB and RETI% results measured at the Department of Laboratory Medicine of the University of Debrecen in 2023 from the laboratory information system (LIS) database. Last year 297 samples were investigated for thalassemia, their laboratory results were collected from LIS. Turnaround time (TAT) was calculated from LIS data in a period before and after the introduction of the new BF algorithm. Results: We found that 16.7% of men (5,495), 16.9% of non-pregnant women (NPW) (7,261), and 27.4% of pregnant women (PW) (825) had HGB levels below the WHO-defined anemia threshold. The number of anemic patients who had RETI% ordered was low, with only 19.9% of anemic men (1,096), 18.9% of anemic NPW (1,371), and 1.45% of anemic PW (12). On the other hand, 51% (944) tests in NPW and 76% (1359) RETI% tests in men were carried out in non-anemic individuals. In case of thalassemia investigation, low MCV was detected in 54% of samples, iron panel could be performed in 30% of patients and those patients having HbA2>3.5% had HBB gene alteration in 90%. With the new BF algorithm routine TAT median of WBC in CSF decreased to 31 min from 84 min and emergency TAT median to 33 min from 78 min (p or < 1.5) were analyzed by ClueGO (gene ontology). We compared the correspondence of genes with abnormal expression in the histopathological lung and platelet samples of a patient with early-stage lung cancer. Results: In early-stage lung tumors, the level of 524 platelet transcripts increased (e.g. MALAT1), while 119 genes decreased significantly (e.g. GATA3) compared to controls. In advanced stage, 757 genes were elevated (e.g. TP53I3) and 198 showed decreased levels (e.g. RUNX3). Platelet genes with abnormal expression are involved in the regulation of intracellular processes, such as cell activation, vesicle secretion, cytoskeletal rearrangement and transcription regulation. Finally, we identified 65 tumor-derived pathological transcripts (e.g. SERPINE2) in platelets, detectable in both lung biopsy and platelet samples. These genes are involved in stress processes. Conclusion: RNA expression in human platelets is significantly altered in lung tumor acting as a potential new diagnostic test for the detection of pulmonary cancer. Abstr. Nr. SE2.5 The role of molecular genotyping in the differential diagnostic workflow of hydatidiform mole Böjtös I., Tardy E.P., Sarkadi E., Simon J., Fülöp V. Central Hospital of Northern Pest-Military Hospital, Budapest, Hungary Background: Hydatidiform mole (HM) is an abnormal gestational disease with elevated β-hCG level, specific ultrasound, histopathologic and genetic alterations. HM can be classified as complete mole (CHM), with an empty ovum fertilized by diploid or two haploid sperms, and partial mole (PHM) being triploid with one maternal and two paternal genomes. HM can progress into gestational trophoblastic neoplasia, so differentiating HM from hydropic abortion (HA) is of utmost importance in further clinical management. As specific histopathologic markers can give discordant results, defining the genetic background provides the most reliable outcome. Ploidy pattern can be defined by conventional karyotyping, fluorescence in situ hybridization or microsatellite analysis (MS-STR), while specifying the number of the paternal chromosome sets is achieved by analysing the methylation pattern of imprinted genes with methylation specific multiplex ligation-dependent probe amplification (MS-MLPA). The latter two require DNA isolated from fresh or paraffin embedded tissue (FFPE). Methods: 291 cytogenetic analyses were done on fresh products of conception (POC) by standard methods. The introduction of MS-STR and MLPA broadened the diagnostic workflow, facilitating the identification of the paternal genome. 8 FFPE samples were analysed because of ambiguous hystopathology finding. Results: 140 POC sample gave abnormal results. From the 19 HM samples 10 were identified as CHM, 9 were classified as PHM. The analysis of 7 FFPE specimens resulted in clear-cut HM diagnosis, one sample was classified as HA. Conclusion: The most optimal workflow for the differential diagnosis of HM starts with karyotyping fresh POC specimen to distinguish between HA and HM. MS-MLPA enables to define the quantity of the paternal genome. Lacking fresh tissue, genotyping FFPE samples with molecular genetic methods is a highly accurate and integral part of the differential diagnosis in our center. Abstr. Nr. SE3.1 Ethical challenges of innovative medical interventions in the face of artificial intelligence Fodor B. 1,2 1 Borsod-Abaúj-Zemplén County Hospital and University Teaching Hospital, Department of Laboratory, Miskolc, Hungary 2University of Miskolc, Faculty of Healthcare Studies, Miskolc, Hungary The rapid advancement of innovative medical technologies is fundamentally transforming cell-level therapeutic and diagnostic possibilities. Theranostics are opening new horizons in precision medicine, while organoids are becoming indispensable in pharmaceutical research as reliable models mimicking human tissues. The use of quantum dots enables in situ visualization of surgical areas, and lab-on-a-chip systems along with next-generation sequencing technologies are challenging traditional scientific paradigms. The digital revolution and the era of big data have inundated physicians and healthcare professionals with an unprecedented volume of information, presenting significant processing challenges. Regenerative medicine now allows for the growth of organs and even embryonic gene manipulation, with the CRISPR-Cas9 system playing a key role. In parallel, biohackers are developing gene therapy agents in non-traditional, even home-based environments, while research into the digitization of consciousness is intensifying. These technological breakthroughs raise serious ethical concerns. The spread of cyberchondria - health anxiety driven by online information - alongside the tension between technological capabilities and the foundational principles of medical ethics (autonomy, non-maleficence, beneficence, and justice), is becoming increasingly evident. Artificial intelligence-based medical algorithms are gaining a greater role in diagnostic and therapeutic decision-making, prompting a re-evaluation of ethical norms and professional responsibilities. This presentation aims to explore key ethical aspects of modern medical procedures in the face of artificial intelligence. Abstr. Nr. SE3.2 Admission D-Dimer Levels Combined With Artificial Intelligence-Supported Imaging Can Help Predict Outcomes in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis Kis B.1,2, Orbán-Kálmándi R.2,3, Lóczi L.2,4, Bomberák D.2,3, Hodossy-Takács R.2,3, Szegedi I.2,5, Nagy A6, Kádár A.Z.2,3, Vasas N.1, Berényi E.1, Harston G.7, Csiba L.4,5, Oláh L.5, Bagoly Z.2,3 University of Debrecen, 1Department of Radiology, 2Lendület "Momentum" Hemostasis and Stroke Research Group of the Hungarian Academy of Sciences, 3Division of Clinical Laboratory Sciences, 4HUN-REN-DE Cerebrovascular Research Group, 5Department of Neurology, 6Department of Preventive Medicine, Debrecen, Hungary; 7Brainomix Ltd., Oxford, UK Background: In acute ischemic stroke (AIS), early prognostic markers are crucial to guide treatment decisions. We aimed to assess whether admission D-dimer levels and artificial intelligence (AI)-supported imaging analysis can serve as predictive tools in AIS patients treated
A Thu, study studied this question.